MoldCo is a digital health platform led by clinicians that aims to make mold detoxification a standard part of preventive healthcare. Recently, the company announced it has successfully secured $8 million in seed funding, co-led by Cantos and Collaborative Fund.
With this latest investment, MoldCo’s total funding has now reached $11 million. The new capital will be instrumental in expanding MoldCo’s innovative virtual clinic and furthering its mission to tackle the pervasive but often overlooked health crisis associated with Mold Toxicity. The goal is to make high-quality, expert-led care for mold-related illnesses more affordable and accessible to patients nationwide.
The issue of mold toxicity is severe and often unrecognized. It is estimated that more than half of U.S. households display signs of mold growth, water damage, or damp conditions. Despite this alarming statistic, many physicians do not routinely screen for or treat mold-related illnesses. This lack of awareness contributes to a significant gap in care, leaving countless individuals without a diagnosis or an effective path to healing. Many people suffering from mold exposure can spend years and thousands of dollars consulting various specialists in search of answers, only to be misdiagnosed. A straightforward screening for Mold Toxicity could provide them with the clarity they desperately need.
Even when mold is identified as the source of health issues, treatment options are often expensive and complicated to obtain. As a result, many individuals endure severe long-term symptoms. One common issue stemming from mold exposure is Chronic Inflammatory Response Syndrome, or CIRS. This debilitating condition is frequently mistaken for other illnesses such as chronic fatigue syndrome, fibromyalgia, or anxiety, causing further confusion and distress for patients.
MoldCo offers a scalable solution to address the challenges of Mold Toxicity care. Instead of continuing to suffer from debilitating symptoms or waiting months for a specialist appointment, patients can immediately access expert, evidence-based Mold Toxicity care through MoldCo’s telehealth platform. Treatment costs average between $150 and $300 per month, which is significantly less than the fragmented care options available elsewhere, which can cost tens of thousands of dollars and may not effectively address the issue due to a lack of specialized knowledge.
MoldCo’s telehealth platform is designed to simplify and enhance the effectiveness of the process. Patients can easily understand their symptoms and access virtual care, with treatments delivered directly to their homes in just a few steps. This comprehensive approach aims to eliminate the accessibility barriers that often complicate the treatment for Mold Toxicity. Through the platform, patients receive on-demand expert care from certified specialists who are extensively vetted. This eliminates geographic limitations and long wait times often associated with traditional healthcare settings.
Additionally, MoldCo offers advanced lab testing that starts at an affordable price point, providing patients with vital information about their condition. The platform also provides access to evidence-based treatment options, including prescription-strength binders and targeted therapies designed for mold-related illnesses. All of this is conveniently shipped directly to the patient’s home, simplifying the treatment process and enabling patients to take charge of their health.
Furthermore, MoldCo understands that navigating healthcare can be overwhelming. That is why the platform features continuous 24/7 support from dedicated care navigators. These professionals guide patients through their medical protocols and help track their progress, ensuring they receive comprehensive care throughout their treatment journey.
Looking ahead, MoldCo has ambitious plans for the future. In the upcoming year, the company will work to expand its network of specialized clinicians across the United States. They also plan to enhance their proprietary care technology, streamline patient onboarding processes, and intensify their efforts in clinical research collaborations. By doing so, MoldCo aims to raise awareness among the public and healthcare professionals about the importance of recognizing and addressing Mold Toxicity.
MoldCo is already making strides in offering advanced lab testing in 46 states and providing care in select states, including Florida, Massachusetts, Michigan, Ohio, and Texas. The company aims to become available to patients nationwide by 2026.
KEY QUOTES:
“My own journey through the confusing and often dismissive landscape of conventional medicine while battling mold illness was frustrating and isolating. It revealed a critical gap: individuals are suffering because the specialized knowledge needed to recognize and effectively treat these conditions is widely unavailable. MoldCo was born from that experience. By combining specialized clinical expertise with telehealth accessibility, we’re making evidence-based care available to everyone who needs it as quickly as possible, at a fraction of the current cost.”
Ariana Thacker, MoldCo founder and CEO
“The profound impact of environmental factors, like those found in water-damaged buildings, on human health and the immune system has been documented for decades. The days of simply living with mold & biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly 30 years of research and evidence-based care, and now being made accessible through MoldCo.”
Dr. Ritchie Shoemaker, a leading physician and foundational researcher in biotoxin illness and CIRS
“The sheer scale of the Mold Toxicity crisis, hidden within the walls of our homes and workplaces and deeply impacting human health, represents exactly the kind of systemic, science-driven challenge Cantos exists to address. Patients have been left navigating a confusing, expensive, and often invalidating system for far too long. MoldCo is not just providing a service; they are building the essential infrastructure for accessible diagnosis and treatment, leveraging technology to bring scientifically validated protocols and expert care directly to those who have been profoundly overlooked. We are convinced they will lead the way in resolving this widespread health challenge.”
Amee Kapadia, Partner at Cantos
“We invest in companies creating a fundamentally better future, and MoldCo directly addresses the critical nexus of our living environments and our long-term health. Their intelligent, telehealth-first approach is precisely what’s needed to democratize access to this specialized care and empower individuals to break cycles of chronic illness linked to mold exposure. We’re proud to support their mission.”
Andrew Montgomery, Partner at Collaborative Fund
